Why the two timelines are not the same decision
When families plan targeted cancer therapy in China, the practical mistake is to merge two questions into one. The first question is clinical: can this centre assess my case, and if so, how would ongoing treatment and monitoring continue? The second question is logistical: when would I need to be in China, for how long, and what would I book? These move at different speeds and are decided by different people.
The clinical answer comes from the treating hospital and its licensed clinicians. They review your records, decide whether the case fits their service, and set out what they would need to confirm before any treatment plan. The travel answer comes only after that clinical step produces something in writing. Booking flights or accommodation before the clinical decision is confirmed means you are financing a schedule that no clinician has agreed to.
This matters especially for targeted therapy, because the decision is not simply about a drug name. Targeted cancer treatment acts on particular molecular features, and biomarker findings can help clinicians assess potential treatment options. That assessment is individual. It is not a general statement that a given drug is available, suitable or appropriate for you in China.
The medical timeline: what actually has to be confirmed
The medical timeline is a sequence of clinical confirmations, not a countdown to departure. It starts with the specific drug and biomarker context. Which molecular feature was identified, in which test, on which sample, and when? Which targeted agents have you already received, and what happened? What is your current treatment, and is your condition stable enough for an overseas review at all?
From there, the centre has to confirm whether it can assess the case. That is a different question from whether it can treat you. A records-based review can clarify whether your biomarker profile and treatment history fit the service the hospital offers, and what additional information the treating team would want. It does not establish final eligibility, and it does not guarantee that any particular therapy will be started.
The third clinical confirmation is continuity. If a targeted therapy were considered, how would ongoing treatment and monitoring continue? Who would supervise cycles, imaging and bloodwork, and how would that connect with your current oncology team at home? These are questions for the treating clinicians, because the answers depend on your diagnosis, your prior treatments and the centre's own protocols. No coordinator decides them.
A useful way to think about it: the medical timeline ends not with a date, but with a written clinical position on your case. Until you have that, the travel timeline has nothing solid to attach to.
The records that decide whether the medical step can move
A clinical review often stalls on a missing or unclear record rather than on any lack of interest from the hospital. For targeted therapy, the documents that carry the most weight are the ones establishing the molecular context and the treatment history, so it is worth checking those first.
Ask your current oncology team which of these exist and how to obtain them: the pathology report, the molecular or genomic test report showing the biomarker result and the method used, imaging reports and the actual images where relevant, a treatment summary listing prior drugs with dates and responses, current medication and dose list, and recent bloodwork. If a test was done at another laboratory, the original report is more useful than a summary line in a clinic letter.
If something is missing, that is information, not a dead end. It tells you what to ask for next. It does not mean you should delay necessary care where you are, and it does not mean a clinician is guessing. It means the review has a specific gap to close before it can give you a meaningful answer.
Send a short summary first rather than a complete archive. A brief outline of the diagnosis, the biomarker result, prior treatments and your main question is enough to start. The team can then tell you which specific documents are needed for the next step.
The travel timeline: what can and cannot be booked yet
Travel arrangements should follow the clinical decision, not lead it. Before a written clinical position exists, the only safe bookings are the ones you can change or cancel. Anything non-refundable assumes a schedule that has not been agreed.
Once the clinical step is confirmed, the travel questions become concrete: which appointment or admission date has actually been offered, what the hospital expects you to bring, how long the initial assessment is expected to take, and what follow-up would look like. Ask the provider to put the appointment confirmation and the expected visit structure in writing, so you are not working from a verbal impression.
Length of stay, report delivery and fitness-to-travel timing are not China-wide facts. They depend on the hospital, the department and your clinical situation. Ask the specific provider what its written plan includes, rather than assuming a standard. If you need a visa, the requirements and processing belong to the relevant authorities; a hospital letter may support an application, but no one can guarantee an outcome.
Practical support such as airport pickup, hotel arrangements and interpretation can be discussed, but these are logistics layered on top of a clinical decision. They do not create one.
How to ask so you get a usable answer
Vague questions produce vague replies. If you ask whether targeted therapy is available in China, you will get a general answer that does not help you plan. If you ask whether a named centre can assess your specific biomarker result and prior drug history, and how ongoing treatment and monitoring would continue, you get something you can act on.
Put your question in writing and keep it narrow. State the diagnosis, the biomarker finding and the test that produced it, the targeted agents already used, your current treatment, and what you want to know. Then ask the centre to confirm, in writing, whether it can assess the case and what it would need next.
Expect a preliminary reply to be exactly that. An initial response may confirm receipt and request records; it is not a treatment decision. Treat any statement about suitability, scheduling or access as provisional until the treating hospital confirms it directly. If a reply is unclear, ask a follow-up question rather than filling the gap with an assumption.
Keep your current oncology team informed throughout. They remain responsible for your care where you are, and they are the people who can supply the records and explain your treatment history accurately.
Where coordination helps, and where it stops
Non-clinical coordination can help with the administrative layer: organising records into a clear summary, requesting a specialist appointment, arranging interpretation, and keeping the two timelines visibly separate so you are not booking travel against an unconfirmed clinical plan. ChinaSpecialistCare can help with records, interpretation and specialist appointment requests for this kind of case, while the hospital and its clinicians decide suitability and treatment.
What coordination cannot do is decide whether you are suitable for a therapy, prescribe or dispense medicines, confirm that a specific drug is available, or promise an appointment, admission or outcome. Those belong to the treating hospital and licensed clinicians. Customs decisions about bringing medicines into China belong to the customs authorities, not to a doctor or a coordinator.
The practical next step is small. Send a brief summary of your diagnosis, biomarker result, prior targeted treatments and your main question through the enquiry form, email or WhatsApp. An initial enquiry is free and does not require buying a proxy consultation. From that summary, the team can tell you what is missing and which clinical question to put to the hospital first. Confirm the medical step in writing, then build the travel timeline around it.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.